Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9H306
UPID:
MMP27_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H306; Q6UWK6
Background:
Matrix metalloproteinase-27 (MMP-27), encoded by the gene with the accession number Q9H306, plays a crucial role in the degradation of extracellular matrix components, including fibronectin, laminin, gelatins, and collagens. This process is vital for tissue remodeling, wound healing, and angiogenesis.
Therapeutic significance:
Understanding the role of Matrix metalloproteinase-27 could open doors to potential therapeutic strategies. Its involvement in the breakdown of the extracellular matrix suggests a pivotal role in diseases characterized by excessive tissue remodeling.